Nucleic Acids Research, 1992, Vol. 20, No. 17 4559-4565
© 1992
MOLECULAR BIOLOGY |
Chimeric DNA-RNA hammerhead ribozymes have enhanced in vitro catalytic efficiency and increased stability in vivo
1Department of Molecular Genetics, Beckman Research Institute of the City of Hope Duarte, CA 91010, USA 2Department of Physiology, Loma Linda University Loma Linda, CA 92350, USA
* To whom correspondence should be addressed
Received May 18, 1992. Revised July 29, 1992. Accepted July 29, 1992.
Subsequent to the discovery that RNA can have site specific cleavage activity, there has been a great deal of interest in the design and testing of trans-acting catalytic RNAs as both surrogate genetic tools and as therapeutic agents. We have been developing catalytic RNAs or ribozymes with target specificity for HIV-1 RNA and have been exploring chemical synthesis as one method for their production. To this end, we have chemically synthesized and experimentally analyzed chimeric catalysts consisting of DNA in the non-enzymatic portions, and RNA in the enzymatic core of hammerhead type ribozymes. Substitutions of DNA for RNA in the various stems of a hammerhead ribozyme have been analyzed in vitro for kinetic efficiency. One of the chimeric ribozymes used in this study, which harbors 24 bases of DNA capable of base-pairing interactions with an HIV-1 gag target, but maintains RNA in the catalytic center and in stem-loop II, has a sixfold greater kcat value than the all RNA counterpart. This increased activity appears to be the direct result of enhanced product dissociation. Interestingly, a chimeric ribozyme in which stem-loop II (which divides the catalytic core) is comprised of DNA, exhibited a marked reduction in cleavage activity, suggesting that DNA in this region of the ribozyme can impart a negative effect on the catalytic function of the ribozyme. DNA-RNA chimeric ulbozymes transfected by cationic liposomes into human T-lymphocytes are more stable than their all-RNA counterparts. Enhanced catalytic turnover and stability in the absence of a significant effect on Km make chimeric ribozymes favorable candidates for therapeutic agents.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Bhindi, R. G. Fahmy, H. C. Lowe, C. N. Chesterman, C. R. Dass, M. J. Cairns, E. G. Saravolac, L.-Q. Sun, and L. M. Khachigian Brothers in Arms: DNA Enzymes, Short Interfering RNA, and the Emerging Wave of Small-Molecule Nucleic Acid-Based Gene-Silencing Strategies Am. J. Pathol., October 1, 2007; 171(4): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kotani, N. Fukuda, H. Ando, W.-Y. Hu, S. Kunimoto, S. Saito, and K. Kanmatsuse Chimeric DNA-RNA hammerhead ribozyme targeting PDGF A-chain mRNA specifically inhibits neointima formation in rat carotid artery after balloon injury Cardiovasc Res, January 1, 2003; 57(1): 265 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Reddy, S. G. Adler, Y.-S. Kim, L. Lanting, J. Rossi, S.-W. Kang, J. L. Nadler, A. Shahed, and R. Natarajan Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells Am J Physiol Renal Physiol, November 1, 2002; 283(5): F985 - F994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mandava, P. Blackburn, D. B. Paul, M. W. Wilson, S. B. Read, E. Alspaugh, R. Tritz, J. R. Barber, J. M. Robbins, and C. A. Kruse Ribozyme to Proliferating Cell Nuclear Antigen to Treat Proliferative Vitreoretinopathy Invest. Ophthalmol. Vis. Sci., October 1, 2002; 43(10): 3338 - 3348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Wang, M. Liu, B. Mullah, D. P. Siderovski, and R. R. Neubig Receptor-selective Effects of Endogenous RGS3 and RGS5 to Regulate Mitogen-activated Protein Kinase Activation in Rat Vascular Smooth Muscle Cells J. Biol. Chem., July 5, 2002; 277(28): 24949 - 24958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Gu, H. Pei, L. Thomas, J. L. Nadler, J. J. Rossi, L. Lanting, and R. Natarajan Ribozyme-Mediated Inhibition of Rat Leukocyte-Type 12-Lipoxygenase Prevents Intimal Hyperplasia in Balloon-Injured Rat Carotid Arteries Circulation, March 13, 2001; 103(10): 1446 - 1452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Teng, N. Fukuda, W.-Y. Hu, M. Nakayama, H. Kishioka, and K. Kanmatsuse DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-{beta}1 mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats Cardiovasc Res, October 1, 2000; 48(1): 138 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Nakaar, B. U. Samuel, E. O. Ngo, and K. A. Joiner Targeted Reduction of Nucleoside Triphosphate Hydrolase by Antisense RNA Inhibits Toxoplasma gondii Proliferation J. Biol. Chem., February 19, 1999; 274(8): 5083 - 5087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Frimerman, P. J. Welch, X. Jin, N. Eigler, S. Yei, J. Forrester, H. Honda, R. Makkar, J. Barber, and F. Litvack Chimeric DNA-RNA Hammerhead Ribozyme to Proliferating Cell Nuclear Antigen Reduces Stent-Induced Stenosis in a Porcine Coronary Model Circulation, February 9, 1999; 99(5): 697 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Morishita, S. Yamada, K. Yamamoto, N. Tomita, I. Kida, I. Sakurabayashi, A. Kikuchi, Y. Kaneda, R. Lawn, J. Higaki, et al. Novel Therapeutic Strategy for Atherosclerosis : Ribozyme Oligonucleotides Against Apolipoprotein(a) Selectively Inhibit Apolipoprotein(a) But Not Plasminogen Gene Expression Circulation, November 3, 1998; 98(18): 1898 - 1904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Wang, B. Mullah, C. Hansen, J. Asundi, and J. D. Robishaw Ribozyme-mediated Suppression of the G Protein gamma 7 Subunit Suggests a Role in Hormone Regulation of Adenylylcyclase Activity J. Biol. Chem., October 10, 1997; 272(41): 26040 - 26048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Scherr, M. Grez, A. Ganser, and J. W. Engels Specific Hammerhead Ribozyme-mediated Cleavage of Mutant N-ras mRNA in Vitro and ex Vivo. OLIGORIBONUCLEOTIDES AS THERAPEUTIC AGENTS J. Biol. Chem., May 30, 1997; 272(22): 14304 - 14313. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fujita, T. Koguma, J. Ohkawa, K. Mori, T. Kohda, H. Kise, S. Nishikawa, M. Iwakura, and K. Taira Discrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli PNAS, January 21, 1997; 94(2): 391 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Puttaraju and M. D. Been Circular Ribozymes Generated in Escherichia coli Using Group I Self-splicing Permuted Intron-Exon Sequences J. Biol. Chem., October 18, 1996; 271(42): 26081 - 26087. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Gu, D. Veerapanane, J. Rossi, R. Natarajan, L. Thomas, and J. Nadler Ribozyme-Mediated Inhibition of Expression of Leukocyte-type 12-Lipoxygenase in Porcine Aortic Vascular Smooth Muscle Cells Circ. Res., July 1, 1995; 77(1): 14 - 20. [Abstract] [Full Text]
|
|